1 active not recruiting, 1 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Oligoprogression: new trials by email Literature Review of Oligoprogression trials Research Report on Oligoprogression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment SBRT and second-line systemic therapy, Second-line systemic therapy - Hepatocellular Carcinoma, Oligoprogression | Phase 2 | Not yet recruiting | Sun Yat-sen University | 70 | 2024-10-01 | 2024-09-19 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Osimertinib, Radiotherapy - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 42 | 2022-01-20 | 2026-01-14 |
Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Radiosurgery (1) · Radiotherapy (1) · osimertinib (1)
AIO-Studien-gGmbH (1) · Sun Yat-sen University (1)
Germany (1)